Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Progenics Pharmaceuticals, Inc. announced the pricing of an underwritten public
offering of 2 million shares of its common stock pursuant to an effective shelf
registration statement. CIBC World Markets and UBS Investment Bank acted as
joint book-running managers for the offering. The price to the public is $15.25,
and proceeds to the company from the offering, net of expenses, are expected
to be approximately $29.3 million.